The 7a-hydroxylation of two cholesterol analogues, sitosterol and cholestanol, and their effect on the 7a-hydroxylation of cholesterol were measured in rat and human hepatic microsomes. In untreated rat liver microsomes, the 7a-hydroxylation of cholesterol was higher than that of cholestanol (1.4-fold) and sitosterol (30-fold). After removal of endogenous sterols from the microsomes by acetone treatment, the 7a-hydroxylation of cholesterol was similar to that of cholestanol and only fourfold higher than that of sitosterol. Cholestanol and sitosterol competitively inhibited cholesterol 7a-hydroxylase in both rat and human liver microsomes, with cholestanol the more potent inhibitor. Patients with sitosterolemia with xanthomatosis, who have elevated microsomal cholestanol and sitosterol, showed reduced cholesterol 7a-hydroxylase activity relative to the activity in control subjects (13.9 and 14.7 vs. 20.3±0.9 pmol/nmol P450 per min, P < 0.01). Enzyme activity in these patients was 40% higher when measured in microsomes from which competing sterols had been removed. Ileal bypass surgery in one sitosterolemic patient decreased plasma cholestanol and sitosterol concentrations and resulted in a 30% increase in hepatic microsomal cholesterol 7a-hydroxylase activity. Cholesterol 7a-hydroxylase appears to have a specific apolar binding site for the side chain of cholesterol and is affected by the presence of cholestanol and sitosterol in the microsomal substrate pool. Reduced bile acid synthesis in sitosterolemia with xanthomatosis may be related to the inhibition of cholesterol 7a-hydroxylase activity by endogenous cholesterol analogues.
Introduction
According to current information, the main pathway for the degradation of cholesterol' in mammals is its conversion into 1 . The following systematic names are given to compounds referred to by trivial names: cholesterol, 5-cholesten-3#-ol; cholestanol, Sa-cholestan-3fl-ol; sitosterol, 24a-ethyl-5-cholesten-3j3-ol; sitostanol, 24a-ethyl-5a-cholestan-3,B-ol; campesterol, 24a-methyl-5-cholesten-3f3-ol; campestanol, 24a-methyl-5a-cholestan-3,-ol; stigmasterol, 24a-ethyl-5,22-cholestadien-3i3-ol; 7a-hydroxycholesterol, 5-cholestene-3fl, bile acids. The major rate-controlling step in bile acid synthesis is the 7a-hydroxylation of cholesterol catalyzed by the microsomal enzyme, cholesterol 7a-hydroxylase (EC 1.14.13.17) . Although newly synthesized cholesterol is the preferred substrate for this enzyme, other hepatic microsomal cholesterol pools can be used for the transformation to bile acids. About 300-500 mg of bile acids are formed daily in humans under normal conditions but, when stimulated, bile acid synthesis can be increased two to threefold. Up to 1 g of cholesterol thus can be 7a-hydroxylated and transformed into bile acids daily via this pathway.
For the past few years, bile acid synthesis has been measured by assessing the activity of hepatic microsomal cholesterol 7a-hydroxylase. The most commonly used assay is the isotope incorporation method, in which radioactive cholesterol is incorporated into the microsomal cholesterol pool and the formation of radioactive 7a-hydroxycholesterol is determined (1) . Results obtained by this method may be confounded by the endogenous pool of microsomal sterols, especially when the size and composition ofthis pool vary. Various cholesterol analogues accompany cholesterol in virtually every mammalian tissue and may affect 7a-hydroxycholesterol formation (2, 3) . Significant amounts of cholestanol are present in the liver of patients with the rare, inherited lipid storage disease cerebrotendinous xanthomatosis (4) , and large amounts of plant sterols, in addition to cholestanol, are deposited in the liver of patients with sitosterolemia with xanthomatosis (5) .
This study describes the 7a-hydroxylation of sitosterol and cholestanol and their effect on the 7a-hydroxylation of cholesterol in human and rat liver microsomal preparations in vitro. Enzyme activities were measured in the absence of endogenous microsomal sterols by a previously validated method that involves the extraction ofendogenous sterols by acetone (1, 6) , and compared with those obtained in untreated microsomes. The effect of the endogenous sterol substrate pool on cholesterol 7a-hydroxylase activity in patients with sitosterolemia with xanthomatosis was also evaluated.
Methods
Human subjects. Six control subjects (aged and two sisters with sitosterolemia with xanthomatosis (aged 24 and 26) were included in the study. Of the six control specimens, four were obtained from the "Liver Tissue Procurement and Distribution System" (National Insti7a-diol; 7,B-hydroxycholesterol, 5-cholestene-3,,7,B-diol; 7a-hydroxycholestanol, 5a-cholestane-3f3,7a-diol; 7f3-hydroxycholestanol, 5a-cholestane-3,B,7,B-diol; 7a-hydroxysitosterol, 24a-ethyl-5-cholestene-3#,7a-diol; 7,B-hydroxysitosterol, 24a-ethyl-5-cholestene-3,B-7#-diol.
tutes of Health contract NO1-DK-62274, University of Minnesota Hospital, Minneapolis, MN) and two were liver biopsies obtained for diagnostic histologic evaluation from normolipidemic subjects with normal liver morphology and function tests. Complete clinical descriptions of the sitosterolemic subjects have been published previously (7) . Liver biopsies were obtained from two untreated sitosterolemic patients and repeated in one patient 9 mo after ileal bypass surgery. (2) . The purified radioactive cholesterol contained < 0.06% 7a-hydroxycholesterol, 0.01% 7,B-hydroxycholesterol, and 0.04% cholestanol as determined by thin-layer chromatography (TLC)2 on a AgNO3-impregnated silica gel G plate (8) and by scintillation counting (Intertechnique SL 4000, Fairfield, NJ). [3a-3H]-Cholestanol (specific activity 1.4 X 107 dpm/Mgmol) was prepared by reduction of 3 mg 5a-cholestan-3-one with 1 mg NaBT4 in 0.5 ml methanol for 2 h. The product was isolated by preparative TLC on silica gel G plates (Brinkmann Instruments, Westbury, NY) using chloroform/acetone (99:1 vol/vol). The major spot, Rf 0.5, was eluted with chloroform/methanol (90:10 vol/vol) and was found to be > 99% pure by TLC and zonal radioactivity scanning. It was further purified by chromatography on a AgNO3-silicic acid column (2) . The purified product contained < 0.04% cholesterol, 0.04% 7a-hydroxycholestanol and 0.0 1% 70-hydroxycholestanol as seen by TLC-scintillation counting. [4-'4C] Sitosterol (Amersham Corp., Arlington Heights, IL) was diluted with unlabeled sitosterol (Supelco, Inc.) to a specific activity of 3.6 X 106 dpm/Mmol and was purified from its oxidation products by column chromatography as described for cholesterol (2) . It was further purified by HPLC on a liquid chromatograph (ALC 201; Waters Associates, Milford, MA) with a refractive index detector (model 401) and a radial-pack ,uBondapak C18 reversed-phase column (I lOm particle size). The mobile phase consisted of methanol/chloroform/ water (90:2:10 vol/vol/vol), at a flow rate of 2 ml/min (operating pressure 2,000 psi). The pure compound was eluted at 24.8 ml (Table I) and contained < 0.05% 7a-hydroxysitosterol, 0.02% 7,3-hydroxysitosterol (as determined by TLC-scintillation counting), 0 (12) .
Sterol determination in hepatic microsomes. Known aliquots of untreated or acetone-treated microsomal suspensions were refluxed for 3 h with 25% KOH in 95% ethanol (wt/vol). Sterols were extracted with n-hexane (6) and analyzed by capillary GLC (13) as trimethylsilyl (TMSi) ether derivatives on a gas chromatograph (model 5890; Hewlett-Packard Co., Palo Alto, CA) equipped with a flame ionization detector and fitted with an open tubular fused silica column (0.32 mm X 26 m) that was internally coated with a 0.21-Mm film of CP Wax 52CB (Chrompack, Inc., Bridgewater, NJ). The following operating conditions were used: injection temperature 275°C; column temperature (isothermal) 210°C, flame ionization detector temperature 295°C, helium carrier gas flow, 1.0 ml/min, and split ratio, 10: 1. Preparation and assay of cholesterol 7a-hydroxylase. Rat livers were excised at -10 a.m. to minimize diurnal variations in bile acid synthesis, and all subsequent operations were carried out at 4°C. Microsomes were isolated and washed as described previously (1). The final pellet was suspended in a buffer (0.1 M potassium phosphate buffer, 20% glycerol, I mM EDTA, 5 mM DTT, and 50 mM NaF, pH 7.4) at a protein concentration, as determined by Lowry et al. (14), of -30 mg protein/ml and stored at -80°C until assayed. To remove endogenous sterols, I ml of the microsomal suspension was added dropwise, with stirring, to 40 ml acetone at -10°C. When the suspension had settled, the precipitate was collected by centrifugation at 1,000 g for 5 min, washed, dried, ground, and stored as described previously (6) . Before use, an aliquot of a known weight of the acetone powder (also referred to as acetone-treated microsomes) was homogenized in the above buffer. The cytochrome P-450 content of the untreated and acetone-treated microsomes was determined from the CO difference spectrum between 450 and 490 nm of the reduced sample using the extinction coefficient of 91 mM-' (15). These acetone-treated microsomal preparations contained 0.2-0.7 nmol P-450 and < 0.4 nmol sterols/mg protein. When acetone-treated microsomes were used, the same assay conditions as described above were used except that 0.025 mg DLPC, solubilized in 0.12 mM Na-DCA, and 2 units of NADPH-cytochrome P-450 reductase were added to the incubation mixture to replace membrane phospholipids and NADPH-cytochrome P-450 reductase lost in the preparation of acetone-treated microsomes. The 7a-hydroxylated products were separated on silica gel G plates without prior acetylation because of the absence of endogenous sterols. The cholesterol 7a-hydroxylase activity in acetone-treated microsomes, assayed in this reconstituted system, was comparable to that of the untreated microsomes and has previously been shown to be similarly affected by bile acid malabsorption (cholestyramine treated) and by cholic acid feeding (6) . We have noted that cytochrome P-420, which is devoid of enzyme activity, is formed in various amounts during the preparation of the acetone powder and if included in the calculations (e.g., when enzyme activity is expressed per milligram protein) it could lead to an underestimation of cholesterol 7a-hydroxylase activity. All results are expressed in picomoles of product formed per nanomole microsomal cytochrome P-450 per minute.
Competitive inhibition assay. To determine the effect of cholestanol and sitosterol on cholesterol 7a-hydroxylase activity in both rat and human acetone-treated microsomes, increasing amounts of unlabeled cholestanol (5-300 AM) or sitosterol (25-300 MM) were added to the assay systems together with the labeled cholesterol substrate. The concentrations of endogenous cholestanol and sitosterol in hepatic microsomes from patients with sitosterolemia and xanthomatosis were at least 5 and 25 MM, respectively, under the assay conditions used.
When the type ofinhibition was determined, varying concentrations of [4-'4C]cholesterol were used with rat acetone-treated microsomes and its conversion to 7a-hydroxycholesterol was measured in the presence of two different concentrations of unlabeled cholestanol or sitosterol (50 and 100 MM for cholestanol, 100 and 200 AM for sitosterol). Double reciprocal plots were used to determine the apparent Km values in the presence and absence of inhibitory sterols.
Statistical significance ofthe data was determined by the unpaired t test. In the comparison of sitosterolemic cholesterol 7a-hydroxylase activities with control values, a normal distribution for the control data was assumed and a 0.01 confidence limit was calculated (18) .
Results 7a-Hydroxylation of cholesterol, cholestanol, and sitosterol. The formation of 7c-hydroxycholesterol (2, 19 ) and 7a-hydroxycholestanol (2) by untreated hepatic microsomes have been reported previously and the same identification procedures of reaction products were used with the acetone-treated microsomes. To obtain enough material to carry out the identification of 7a-hydroxysitosterol, the products from largescale (300-500-fold) incubation mixtures were combined and purified by TLC as described in Methods. The fraction corresponding to 7a-hydroxysitosterol (Rf = 0.4) was subjected to GLC analysis after trimethylsilylation, and was found to have an identical retention time to synthetic 7a-hydroxysitosterol (3). Its specific radioactivity after dilution with authentic unlabeled 7a-hydroxysitosterol (1,100 dpm/Mmol) remained constant after crystallization from acetone/water and methanol/ water.
Optimal assay conditions for the 7a-hydroxylation of cholestanol and sitosterol were determined and compared with those of cholesterol, using acetone-treated microsomal preparations that contained < 0.4 nmol endogenous sterols per milligram protein (Fig. 1) . The rates of formation of the 7a-hydroxylated products were linear up to 1 liM cytochrome P-450 (Fig. 1 A) . Reaction rates were proportional to the incubation time during the first 20 min (Fig. 1 B) . The enzyme appeared to be saturated when the sterol concentration reached 200 ,uM (Fig. 1 C) . The apparent Km value of 46 ,uM observed with acetone-treated microsomes was lower than the range of 80-225 itM reported for untreated microsomes (20) (21) (22) and closer to the value of 15 AM observed with butanol/acetonetreated microsomes (23) .
Substrate specificity. Fig. 2 shows sterol 7a-hydroxylase activity with cholesterol, cholestanol, and sitosterol as substrates, determined in untreated (Fig. 2 A) and acetone-treated (Fig. 2 B) greater for cholesterol than for sitosterol and 1.4 times greater than for cholestanol (P < 0.0002) when measured in the untreated microsomes (Fig. 2 A) . When the incubation was carried out with the acetone-treated microsomes from which endogenous cholesterol had been removed (Fig. 2 B Enzyme inhibition and kinetics. The effect of cholestanol and sitosterol on the 7a-hydroxylation of cholesterol is demonstrated in Figs. 3 and 4 . In these experiments, incubations were carried out with increasing amounts of unlabeled cholestanol or sitosterol added to acetone-treated microsomes. Radioactive cholesterol was the substrate and labeled 7a-hydroxycholesterol was the product measured. The results show that cholestanol is a far more potent inhibitor of cholesterol 7a-hydroxylation than sitosterol, probably because of its greater affinity for the enzyme as compared with sitosterol (Fig. 2) . In the rat, sitosterol (100 gM) inhibited cholesterol 7a-hydroxylase activity 30%, whereas 100 1AM cholestanol inhibited it 60% (Fig. 3) . In acetone-treated microsomes from human liver, 100 1AM sitosterol and 50 gM cholestanol inhibited cholesterol 7a-hydroxylase activity -40% (Fig. 4) . For the determination of the type of inhibition, enzyme activities were measured in acetone-treated rat liver microsomes with two different concentrations of cholestanol or sitosterol and increasing concentrations of labeled cholesterol substrate (Figs. 5 and 6 ). The Lineweaver-Burk double reciprocal plots showed straight lines that intersected at the same point on the ordinates, indicating competitive inhibition of cholesterol 7a-hydroxylase by cholestanol and sitosterol.
/S, (,uM) To test the effect of microsomal sterols on cholesterol 7a-hydroxylase activity in a clinical situation, the activities of cholesterol 7a-hydroxylase were measured in untreated and acetone-treated microsomal preparations obtained from two patients with sitosterolemia with xanthomatosis and compared with those of six control subjects (Table II) . Sterol concentrations were determined in both acetone-treated and untreated microsomes. The cholesterol 7a-hydroxylase activity observed in untreated microsomes was substantially lower in the two sitosterolemic patients than in control subjects (13.9 and 14.7 compared with the control mean±SEM of 20.3±0.9 pmol/nmol P-450/min, P < 0.01). The lower cholesterol 7a-hydroxylase activity in the sitosterolemic microsomes was associated with significantly higher concentrations of endogenous cholestanol and plant sterols that amounted to 18% ofthe microsomal sterol pool. After treatment with acetone to remove endogenous sterols, sitosterolemic microsomal cholesterol 7a-hydroxylase activity increased 40% when assayed in the reconstituted system, which contained optimal amounts of cholesterol. In these experiments, with either untreated or reconstituted sitosterolemic microsomes, only the conversion of cholesterol to 7a-hydroxycholesterol was measured. The decrease in cholesterol 7a-hydroxylase activity in the untreated microsomes from the patients with sitosterolemia with xanthomatosis thus may reflect competitive inhibition by the coexisting endogenous cholesterol analogues (cholestanol, plant sterols, and their 5a-stanols). Ileal bypass surgery in one sitosterolemic subject decreased plasma cholestanol and plant sterols from 29 to 15 mg/dl and was accompanied by a 30% increase in cholesterol 7a-hydroxylase activity in untreated microsomes (from 13.9 to 17.9 pmol/nmol P-450/min).
Discussion
The results ofthis investigation emphasize the important effect of the microsomal sterol substrate pool on cholesterol 7a-hydroxylase activity. Optimal assay conditions were determined for measuring the 7a-hydroxylation of cholestanol and sitosterol in comparison to cholesterol in acetone-treated microsomes from which virtually all endogenous sterols had been removed. The enzyme was assayed at saturation levels of substrate (200 zM), with enzyme concentration of 0.2-1.0 uM P-450 and incubation time of 10 min that were in the linear range of enzyme activity (Fig. 1, A-C) . The membrane phospholipids lost during acetone treatment of the microsomes were replaced in the incubation mixture with DPLC, the major constituent of liver membrane phospholipids (24) . The amount of Na-deoxycholate used to solubilize DLPC was shown previously not to inhibit microsomal cholesterol 7a-hydroxylase (2). Individual phospholipids were not identified since these lipids apparently do not act directly on cholesterol 7a-hydroxylase but facilitate interaction of the enzyme with NADPH-cytochrome P-450 reductase and can be replaced by an excess of the latter (25). Triton X-100 (0.15%) was used as a solubilizing agent for the substrates and was found to yield comparable enzyme activities to 0.3% Triton WR-1339 but higher activities than Cutscum or Tween-80 used in earlier assays (6) . The total sterol concentration that could be used with 0.15% Triton X-100 did not exceed 300 ,M (Fig. 6, inset) .
Over this concentration, high variability of enzyme activity in replicates was observed, possibly due to incomplete solubilization of the sterols. Under the assay conditions used in these experiments, the variation coefficient of cholesterol 7a-hydroxylase activity of the acetone-treated microsomes was < 6%. ( 17) to avoid underestimation by dilution with the endogenous cholesterol pool. When acetone-treated microsomes were used, the isotope incorporation method was used as described in Methods. The numbers represent means±SEM of six control subjects and the averages of two patients with sitosterolemia and xanthomatosis. § Significantly lower than controls (P < 0.01).
The concentrations of endogenous cholestanol and sitosterol present in the in vitro assay of the untreated microsomes from sitosterolemic patients were > 5 and > 25 uM, respectively, based on the use of 2-3 mg microsomal protein in a total volume of 0.5 ml incubation mixture.
In the study of substrate specificity, cholestanol was selected as the substrate because it contains the identical isooctyl side chain as cholesterol but does not retain its A5-steroid nucleus. The plant sterol, sitosterol, was selected because it differs from cholesterol only by its additional ethyl substituent at C-24 of the side chain. Both compounds are present in abundant amounts in microsomes of patients with sitosterolemia with xanthomatosis (Table II) . The affinity of the 7a-hydroxylating enzyme toward these substrates was evaluated in acetone-treated microsomes (Fig. 2 B) . It was greatest for cholesterol and poorest for sitosterol. Cholestanol, which has the same isooctyl side chain as cholesterol, exhibited almost the same affinity toward the enzyme. The difference in the nuclear structure did not interfere with the enzymatic hydroxylation of cholestanol. These findings are consistent with the results of Bergstrom et al. (26) and Boyd et al. (27) , who studied the 7a-hydroxylation of several cholesterol analogues and suggested that cholesterol 7a-hydroxylase has a specific binding site for the apolar side chain of cholesterol. This binding site may be required for the orientation of the substrate on the enzyme to allow the hydroxylation to occur stereospecifically at the 7a-position. When the 7a-hydroxylation of sitosterol was carried out with the untreated microsomes, it was barely detectable, as has been observed earlier by Aringer and Eneroth (3) and by Boyd et al. (27) , but showed an eightfold increase upon removal of endogenous cholesterol (Fig. 2 B) . Similarly, the 7a-hydroxylation of cholestanol was lower in untreated relative to acetone-treated microsomes. This suggests that the large microsomal cholesterol pool competes with sitosterol and cholestanol and partially masks their 7a-hydroxylation. Only when the microsomal cholesterol pool is removed by acetone treatment is the 7a-hydroxylation of sitosterol shown to be significant.
In this study, cholestanol was shown to inhibit cholesterol 7a-hydroxylase activity up to 75%, whereas sitosterol inhibited it maximally 40% (Fig. 3) . In earlier studies with the rat, low inhibition ofcholesterol 7a-hydroxylase by cholestanol (2) and lack of inhibition by sitosterol (3) have been reported and were probably due to the confounding effect of the endogenous microsomal cholesterol pool in the untreated microsomes that were used. The double reciprocal plots demonstrated that both cholestanol and sitosterol were competitive inhibitors of cholesterol (Figs. 5 and 6 ). The apparent Km of cholesterol 7a-hydroxylase measured in the presence of 50 ,uM cholestanol or 100 ,uM sitosterol was 87 ,M compared with the Km of 46 ,AM observed in the absence of any added inhibitor. With 100 AM cholestanol, the apparent Km increased to 117 ,tM. Thus, cholestanol is a potent inhibitor ofthe conversion ofcholesterol to its 7a-hydroxylated derivative and has similar affinity as cholesterol toward cholesterol 7a-hydroxylase. Sitosterol, on the other hand, is a less effective inhibitor, has much less affinity for the enzyme and can be 7a-hydroxylated up to 26% relative to the 7a-hydroxylation of cholesterol when competing endogenous cholesterol is removed.
In this study, we have demonstrated for the first time that human liver microsomal cholesterol 7a-hydroxylase activity is preserved after the removal of endogenous sterols by acetone treatment. In human liver, as in the rat, 50 ,uM cholestanol or sitosterol inhibited cholesterol 7a-hydroxylase activity 35 or 16%, respectively. The importance of this observation concerns cholesterol 7a-hydroxylase activity in the rare inherited lipid storage disease, sitosterolemia with xanthomatosis, in which the overabsorption of plant sterols leads to the accumulation of sitosterol and 5a-saturated stanols in all tissues, including the liver (5) . The reduced cholesterol 7a-hydroxylase activity in the patients' untreated microsomes relative to controls was associated with increased amounts of endogenous cholestanol and plant sterols (Table II) . Removal of endogenous sterols by acetone treatment of the microsomes resulted in a 40% increase in cholesterol 7a-hydroxylase activity in the sitosterolemic specimens but did not affect the enzyme activity in the control specimens. When cholestanol or sitosterol was added to human acetone-treated microsomes (Fig. 4) at concentrations (10 or 50 ,M) that were similar to those present in assays of untreated microsomes from patients with sitosterolemia with xanthomatosis, cholesterol 7a-hydroxylase activity was reduced 9 and 16%, respectively. The greater inhibitory effect on enzyme activity of endogenous cholesterol analogues observed in microsomes from patients with sitosterolemia and xanthomatosis (40%, Table II) may be due to the presence of additional endogenous cholesterol analogues such as campesterol. Preliminary experiments in our laboratory showed that campesterol, the second most abundant plant sterol in the patients' microsomal samples, inhibited cholesterol 7a-hydroxylase activity to a similar extent as sitosterol. In addition, the higher inhibitory effect of endogenous cholesterol analogues relative to that observed with exogenous inhibitors may be due to greater availability of endogenous substrate/inhibitors (28).
After ileal bypass surgery, endogenous sterols and 5a-stanols decreased 50% and hepatic cholesterol 7a-hydroxylase activity increased 30%. The rise in activity may be due to both a partial removal of competing cholesterol analogues and an induction of enzyme activity by the interruption of the enterohepatic circulation (2) . Recently, Miettinen et al. (29) and Ilias et al. (30) reported that gallstones and bile from patients with cholelithiasis contained substantial amounts of cholestanol, plant sterols, and cholesterol precursors. Further, decreased bile acid pools (31) and low cholesterol 7a-hydroxylase activities (32) have been reported in patients with cholelithiasis. It is tempting to speculate that the lower bile acid synthesis in this condition relates to competitive inhibition of cholesterol 7a-hydroxylase by the associated abnormal microsomal sterol environment. It is important to emphasize that it is difficult to extrapolate an in vitro enzyme activity, expressed as picomole product formed per nanomole cytochrome P-450 per minute, to a daily bile acid synthetic rate expressed in milligrams bile acids formed per kilogram body weight per day. However, cholesterol 7a-hydroxylase activity reflects the rate of bile acid synthesis since increased or decreased enzyme activity, as measured in vitro, correlates with higher or lower bile acid production rates determined in vivo (2, 33) . The conversion of sitosterol and cholestanol to primary bile acids has been demonstrated in humans (34) and rats (35, 36) 
